Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Ratings for Hims & Hers Health (NYSE:HIMS) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 0 | 5 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 0 | 2 | 0 | 0 |
2M Ago | 1 | 0 | 1 | 0 | 0 |
3M Ago | 2 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.11, with a high estimate of $26.00 and a low estimate of $18.00. Observing a 31.53% increase, the current average has risen from the previous average price target of $16.81.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Hims & Hers Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Korinne Wolfmeyer | Piper Sandler | Maintains | Neutral | $18.00 | $18.00 |
Jailendra Singh | Truist Securities | Raises | Hold | $23.00 | $13.00 |
Jonna Kim | TD Cowen | Raises | Buy | $25.00 | $15.00 |
Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $18.00 | $16.00 |
Glen Santangelo | Jefferies | Raises | Hold | $23.00 | $14.00 |
Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
Maria Ripps | Canaccord Genuity | Raises | Buy | $24.00 | $20.00 |
Daniel Grosslight | Citigroup | Raises | Neutral | $20.00 | $16.00 |
Capture valuable insights into Hims & Hers Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Hims & Hers Health's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 45.81%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Hims & Hers Health's ROE excels beyond industry benchmarks, reaching 3.23%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Hims & Hers Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: HIMS